Praluent, alirocumab
Named-patient access overview. Praluent is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice.
About Praluent
Praluent (alirocumab) is a fully human monoclonal antibody manufactured by Sanofi and Regeneron. It is a PCSK9 inhibitor, indicated as an adjunct to diet and maximally tolerated statin therapy in adults with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and for the reduction of cardiovascular risk in adults with established cardiovascular disease. Praluent works by binding to PCSK9, a protein that regulates the recycling of LDL receptors on liver cells, increasing the liver's capacity to clear LDL cholesterol from the blood.
Praluent is administered as a subcutaneous injection, typically every two weeks or once monthly depending on the prescribed regimen. It is supplied in pre-filled pens or syringes and requires refrigerated handling between 2 and 8 degrees Celsius until use. Patients can briefly store the medicine at room temperature before injection, within the limits specified in the manufacturer's prescribing information.
For international patients whose home-country formulary either does not list Praluent, lists it with restrictive prior-authorization criteria, or imposes long waiting periods, US-sourced supply via a named-patient pathway is often the most direct route to consistent therapy.
Who Praluent is for
Praluent is generally considered for adults who have not reached their LDL-cholesterol goal on maximally tolerated statin therapy, those who are statin-intolerant, patients with heterozygous or homozygous familial hypercholesterolemia, and patients with established atherosclerotic cardiovascular disease who remain at high residual risk. The decision to initiate Praluent rests with the treating physician, who weighs lipid targets, cardiovascular risk profile, comorbid conditions, and prior therapy response.
How Reserve Meds coordinates Praluent
- Patient or treating physician submits a named-patient request through the Reserve Meds intake.
- Our clinical team reviews appropriateness of Praluent for the patient's lipid profile, cardiovascular history, and destination country.
- The treating physician issues a prescription and a brief clinical justification.
- Country-specific named-patient program or personal-import documentation is prepared.
- Praluent is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability from manufacturer to patient.
- Shipment is coordinated to the patient's physician, hospital pharmacy, or approved address, with refrigerated handling end-to-end.
Pricing and what shapes it
Praluent's landed price for international patients is shaped by the wholesale acquisition cost in the United States, destination-country import duties and value-added tax, cold-chain logistics fees, and the Reserve Meds coordination fee. We do not publish a single global price because each of those layers shifts by country and by quantity dispensed. Once intake is complete and the destination is confirmed, our coordinator issues a firm quote in writing covering the full landed cost before any wire is requested.
Timing expectations
From the moment a complete intake is received, indicative timing for Praluent to reach a patient in our priority markets ranges from approximately two to five weeks. The dominant variables are the speed at which the destination-country regulator processes named-patient paperwork, the patient's ability to provide a complete physician package, and cold-chain transit. Reserve Meds tracks each case through a single named coordinator so the patient and physician always know what stage the case is in.
Access by country
Reserve Meds publishes a detailed country deep-dive for Praluent in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
Cold-chain handling, in plain language
Praluent must remain refrigerated between 2 and 8 degrees Celsius from the wholesaler all the way to the patient's refrigerator. Reserve Meds uses validated thermal packaging with continuous temperature monitoring on every shipment. If a sensor records a temperature excursion in transit, the affected unit is quarantined and replaced; the patient is never asked to inject medication from a compromised package.
Documentation the physician will be asked to provide
The typical package includes a current prescription, a brief clinical justification letter, a copy of the physician's license, recent lipid-panel results, and the destination-country named-patient or personal-import form where applicable. Reserve Meds prepares the country-specific paperwork; the physician supplies the clinical pieces. We aim to keep the physician's workload to under thirty minutes per case.
Privacy and data handling
Patient information collected through Reserve Meds intake is handled under HIPAA standards in the United States and the privacy regimes that apply in the destination country, including UAE PDPL, KSA PDPL, India DPDPA, and the EU GDPR where relevant. We share only the minimum necessary information with the prescribing physician, the wholesaler, the carrier, and any regulator who requires submission.
Start a request for Praluent
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserved for you.